Department of Hematology, Juntendo University School of Medicine, Japan.
Department of Cell Therapy and Transfusion Medicine, Juntendo University School of Medicine, Japan.
Intern Med. 2023 Feb 15;62(4):601-604. doi: 10.2169/internalmedicine.0130-22. Epub 2022 Jul 5.
Methotrexate-associated lymphoproliferative disorders (MTX-LPDs) with diffuse large B-cell lymphoma (DLBCL) pathology present with high rates of spontaneous regression after methotrexate (MTX) termination, especially in Epstein-Barr virus-encoded RNA (EBER)-positive cases. DLBCL with adrenal involvement is known for an extremely dismal prognosis. However, the prognosis of adrenal DLBCL in the context of MTX-LPD is unknown. We herein report two EBER-positive adrenal DLBCL MTX-LPD patients who achieved long-term remissions of 22 and 40 months with MTX termination alone. Both patients are doing well with no relapse at the time of reporting. Unlike adrenal DLBCL in general, adrenal involvement may not be a poor prognostic factor when restricted to DLBCL MTX-LPDs.
甲氨蝶呤相关性淋巴增生性疾病(MTX-LPD)伴弥漫性大 B 细胞淋巴瘤(DLBCL)病理,在甲氨蝶呤(MTX)停药后有很高的自发消退率,尤其是在 Epstein-Barr 病毒编码 RNA(EBER)阳性病例中。伴有肾上腺受累的 DLBCL 预后极差。然而,MTX-LPD 背景下的肾上腺 DLBCL 的预后尚不清楚。本文报告了 2 例 EBER 阳性的肾上腺 DLBCL MTX-LPD 患者,他们仅通过停止 MTX 治疗就分别获得了 22 个月和 40 个月的长期缓解。截至报告时,两名患者均状况良好,无复发。与一般的肾上腺 DLBCL 不同,当仅限于 DLBCL-MTX-LPD 时,肾上腺受累可能不是一个预后不良的因素。